Neuroimaging Studies

该中心的主要目标是开发和评估戒烟前的适应性治疗。该项目的首要目标是评估戒烟前药物作用的神经机制。在一个平行的设计项目1。临床试验（PD：Rose），100名吸烟者将被分配到四个治疗组之一。在所有四组中，参与者将在戒烟前两周内吸烟他们常用的香烟品牌。对照组（CNTRL）将在戒烟日期前两周佩戴安慰剂贴剂。第二组将在戒烟日期前两周贴敷21 mg/d贴剂（仅NRT）。第三组将在第二周从佩戴尼古丁贴片转为服用伐伦克林（NRT）。第四组将在第二周服用安非他酮SR和NRT（NRT+BUP）。参与者将在tiaseline接受扫描，并在戒烟后12小时再次接受扫描。 在扫描过程中，我们将测量大脑对吸烟线索的反应和脑血流。将确定戒烟前药物治疗的常见和独特效果。基于初步的数据，我们假设戒烟前的治疗将导致较低的大脑对吸烟线索的反应和戒烟后的脑血流量。我们还假设基线大脑功能可以预测戒烟前后的治疗反应。拟议的项目以调查小组的经验为基础 并与中心的其他项目和核心高度融合。

The primary aim of the proposed center is to develop and evaluate pre-cessafion adapfive treatments for cigarette addiction. The overarching goal of this project is to evaluate the neural mechanisms that underiie pre-cessation medication effects. In a design paralleling Project 1. Clinical Trials (PD: Rose), 100 smokers will be assigned to one of four treatment arms. In all four arms, participants will confinue to smoke their usual brand of cigarettes in the two weeks prior to quitting smoking. The control (CNTRL) group will wear a placebo patch in the two weeks prior to their quit date. A second group will wear a 21 mg/d patch for the two weeks prior to the quit date (NRT-Only). A third group will switch from wearing a nicotine patch to taking varenicline in the second week (NRT¿¿VAR). A fourth group will take bupropion SR in addition to NRT in the second week (NRT+BUP). Participants will be scanned at tiaseline and again 12 hrs after quitting smoking. During scanning, we will measure brain reactivity to smoking cues and cerebral blood fiow. Common and unique effects of pre-cessation pharmacotherapies will be identified. Based on preliminary data, we hypothesize that pre-cessation treatment will result in lower brain reactivity to smoking cues and cerebral blood flow following quitfing smoking. We also hypothesize that baseline brain funcfion will be predictive of pre- and post-quit treatment response. The proposed project builds upon the investigative team's experience and is highly integrated with the center's other projects and cores.